The company was stablished on March 2017 by professors Dr. A. Villaverde and Dra. E. Vázquez from the Nanobiotecnology Group of the UAB, professor Dr. R. Mangues from the Research Institut of Hospital de Sant Pau, and entrepreneur Dr. M. Rodríguez.
M. Cano, MBA PhD
CEO of Nanoligent. Has been developing her career as a Operational Project Manager and Project Leader involved in several preclinical and clinical projects.
A. Villaverde, PhD
Full professor at the Universitat Autònoma de Barcelona and Nanobiotechnology group co-leader at the Institut de Biotecnologia i Biomedicina.
E. Vázquez, MD PhD
Principal investigator and co-leader of the Nanobiotechnology group at the Institute of Biotechnology and Biomedicine, Universitat Autònoma de Barcelona.
R. Mangues, PharmD PhD
Full Professor and head of the Oncogenesis and Antitumor Drug Group at the Biomedical Research Institut Sant Pau of the Hospital de la Santa Creu i Sant Pau.
M. Rodríguez, MBA PhD
Entrepreneur and founder of Nanoligent. Has experience in marketing, operations, and finance within the pharmaceutical industry.
We cooperate with the following top world-class research centers: